Adaptimmune Therapeutics (ADAP) Prices 21 Million Offering at $4/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
January 22, 2020 8:48 AM ESTPHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Adaptimmune)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (ADSs) at a price to the public of $4.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 3,150,000 ADSs at the public offering price. The gross offering size for this offering is expected to be approximately $84.0 million, excluding any exercise of the underwriters'... More
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
January 21, 2020 4:08 PM ESTPHILADELPHIA, Pa. and OXFORD, UK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (ADSs) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the public... More
